App-Quantinova.ai

Prevalence, recurrence, and cost burden of locally advanced basal cell carcinoma (BCC) not amenable to surgery or radiotherapy in the UK.

John Lear - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Basal cell carcinoma

N/A

Symptom assessment in patients with JAK inhibitor naive and JAK inhibitor failed myelofibrosis.

Yun Su - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

N/A

Differences between Japan and rest of world (ROW) in disease presentation and outcome of previously treated adult t-cell leukemia-lymphoma (ATL) using therapy with a monoclonal antibody to CCR4, mogamulizumab (moga).

Adrienne Alise Phillips - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adult T-Cell Leukemia

Mogamulizumab

Expression of PD-L1, PD-L2 and PD-1 in thymic epithelial tumours (TETs).

Spyridon Gennatas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Epithelial tumors

N/A

Thymoma and thymic carcinoma case series: The Christie Hospital.

Alicia Conway - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thymic carcinoma

N/A

Effectiveness of cytotoxic agent etoposide after biological therapy in advanced thymic tumours.

Vincenzo Damiano - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thymic carcinoma

Somatostatin

Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).

James Chih-Hsin Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Crizotinib

Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC).

Kelvin Young - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Carboplatin

The impact of osimertinib on function and health status for patients with EGFR mutation-positive advanced non-small cell lung cancer.

Katja Rudell - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Tagrisso

Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer.

Jin-Ji Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Savolitinib

UK experience of combined BRAF and MEK inhibition with dabrafenib and trametinib (D+T) in the metastatic melanoma (MM) named patient programme.

Sarah Gabrielle Ellis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Dabrafenib Mesylate

International comparison of BRAF testing in melanoma.

Marcos Tadeu dos Santos - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

A confirmatory survey regarding public misconception about cardiopulmonary resuscitation (CPR) in advanced cancer patients.

Santhanam Sundar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

An analysis of thank-you notes to an oncologist.

Melanie J. Mackean - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Metastatic germ cell tumours (mGCT) treatment and outcomes in patients aged 50 years in west of Scotland.

Ishtiaq Husain Zubairi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

An observational cohort study on terminal cancer survivors practicing falun gong (FLG) in China.

Yuhong Dong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Multicenter case registry study on medication-related osteonecrosis of the jaw in advanced cancer patients.

Morten Schiodt - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Should ASCO re-examine the febrile neutropenia threshold for primary G-CSF prophylaxis in breast cancer?

Tallal Younis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Filgrastim

Therapeutic imatinib monitoring in patients with gastrointestinal stromal tumours.

Pavlina Spiliopoulou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Imatinib

Simultaneous EGFR mutation detection and copy number assessment in circulating tumour DNA (ctDNA) to inform molecular methods of therapy resistance and plasma ctDNA content in lung adenocarcinoma.

Alexandra Pender - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Filters

45280 Abstracts